Ariane Laparra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ariane Laparra has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Aurelien Marabelle
University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France
20 shared publications - Jean-Marie Michot
Institut Gustave Roussy 1 Drug Development Department Villejuif, France
14 shared publications - François-Xavier Danlos
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
13 shared publications - Stephane Champiat
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
13 shared publications - Antoine Hollebecque
Gustave Roussy, Villejuif, France
12 shared publications - Capucine Baldini
Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy Cancer Campus, Université Paris-Saclay, 94805 Villejuif, France
12 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
CONSORT flow diagram of participant enrollment and study analysis. *Trial identifiers are confidential and could not be disclosed. DITEP, Drug Development Department.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
CONSORT flow diagram of participant enrollment and study analysis. *Trial identifiers are confidential and could not be disclosed. DITEP, Drug Development Department.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for OS according to the GRIm score. OS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median OS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for OS according to the GRIm score. OS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median OS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for PFS according to the GRIm score. PFS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median PFS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot, except for C, in which every patient from the high-risk group had progressive disease before the first in the other group.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for PFS according to the GRIm score. PFS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median PFS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot, except for C, in which every patient from the high-risk group had progressive disease before the first in the other group.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of OS.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of OS.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for OS according to the GRIm score in patients treated with TCE in monotherapy.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for OS according to the GRIm score in patients treated with TCE in monotherapy.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of PFS.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of PFS.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for PFS according to the GRIm score in patients treated with TCE in monotherapy.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for PFS according to the GRIm score in patients treated with TCE in monotherapy.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients according to the GRIm score.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients according to the GRIm score.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (10) , 2339-2349
Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
The Gustave Roussy Immune (GRIm) score, based on the neutrophil-to-lymphocyte ratio, serum albumin, and lactate dehydrogenase, is a validated prognostic marker in patients receiving immune checkpoint blockers (ICB). We evaluated its prognostic value in patients treated with bispecific CD3 T-cell engagers (TCE) in phase I trials. We retrospectively analyzed prospectively collected data from 150 patients treated with TCEs alone or combined with ICBs across 11 phase I trials at the Drug Development Department, Gustave Roussy (June 2016–February 2025). Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier methodology and Cox regression models. Discriminatory performance was assessed using Harrell C-index. Among 150 patients, 127 (85%) had solid tumors, and 23 (15%) had hematologic malignancies; 81% were classified as low-risk GRIm score. Low GRIm score was associated with improved OS [hazard ratio (HR), 0.29; 95% confidence interval (CI), 0.17–0.47; P < 0.001; median OS, 17.6 vs. 5 months] and PFS (HR, 0.57; 95% CI, 0.36–0.89; P = 0.01; median PFS, 2.8 vs. 1.6 months). In solid tumors, the GRIm score remained prognostic for OS (HR, 0.41; P = 0.002) but not for PFS. In hematologic malignancies, it strongly predicted both OS (HR, 0.04; P < 0.001) and PFS. Multivariable analyses confirmed the GRIm score as independently prognostic for OS (HR, 0.29; P < 0.001) and PFS (HR, 0.60; P = 0.035). Similar findings were observed in patients receiving TCE in monotherapy. The GRIm score independently predicts outcomes in patients receiving TCEs in phase I trials and may support patient selection, particularly in hematologic malignancies. Significance: This study validates the use of the GRIm score as a prognostic tool for patients treated with TCE in early-phase trials. It discriminates between low- and high-risk patients across solid and hematologic malignancies and supports the integration of simple biomarkers into patient selection and risk stratification for bispecific CD3 therapies, improving trial design and remaining feasible in routine clinical practice settings.
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (10) , 2339-2349
Open AccessGustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
The Gustave Roussy Immune (GRIm) score, based on the neutrophil-to-lymphocyte ratio, serum albumin, and lactate dehydrogenase, is a validated prognostic marker in patients receiving immune checkpoint blockers (ICB). We evaluated its prognostic value in patients treated with bispecific CD3 T-cell engagers (TCE) in phase I trials. We retrospectively analyzed prospectively collected data from 150 patients treated with TCEs alone or combined with ICBs across 11 phase I trials at the Drug Development Department, Gustave Roussy (June 2016–February 2025). Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier methodology and Cox regression models. Discriminatory performance was assessed using Harrell C-index. Among 150 patients, 127 (85%) had solid tumors, and 23 (15%) had hematologic malignancies; 81% were classified as low-risk GRIm score. Low GRIm score was associated with improved OS [hazard ratio (HR), 0.29; 95% confidence interval (CI), 0.17–0.47; P < 0.001; median OS, 17.6 vs. 5 months] and PFS (HR, 0.57; 95% CI, 0.36–0.89; P = 0.01; median PFS, 2.8 vs. 1.6 months). In solid tumors, the GRIm score remained prognostic for OS (HR, 0.41; P = 0.002) but not for PFS. In hematologic malignancies, it strongly predicted both OS (HR, 0.04; P < 0.001) and PFS. Multivariable analyses confirmed the GRIm score as independently prognostic for OS (HR, 0.29; P < 0.001) and PFS (HR, 0.60; P = 0.035). Similar findings were observed in patients receiving TCE in monotherapy. The GRIm score independently predicts outcomes in patients receiving TCEs in phase I trials and may support patient selection, particularly in hematologic malignancies. Significance: This study validates the use of the GRIm score as a prognostic tool for patients treated with TCE in early-phase trials. It discriminates between low- and high-risk patients across solid and hematologic malignancies and supports the integration of simple biomarkers into patient selection and risk stratification for bispecific CD3 therapies, improving trial design and remaining feasible in routine clinical practice settings.